3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Unknown
4
Completed
4
Withdrawn
1
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Classical hematology
1
Conditions
Prostatic Neoplasms
595
Carcinoma, Renal Cell
276
Urinary Bladder Neoplasms
175
Kidney Neoplasms
112
Neoplasms
101
Neoplasm Metastasis
94
Carcinoma, Non-Small-Cell Lung
94
Carcinoma, Transitional Cell
86
Melanoma
85
Breast Neoplasms
83
Ovarian Neoplasms
64
Lung Neoplasms
50
Colorectal Neoplasms
50
Pancreatic Neoplasms
43
Stomach Neoplasms
40
Sarcoma
37
Squamous Cell Carcinoma of Head and Neck
35
Triple Negative Breast Neoplasms
31
Testicular Neoplasms
29
Uterine Cervical Neoplasms
27
Esophageal Neoplasms
26
Carcinoma, Hepatocellular
26
Head and Neck Neoplasms
24
Non-Muscle Invasive Bladder Neoplasms
23
Small Cell Lung Carcinoma
22
Colonic Neoplasms
20
Urologic Neoplasms
17
Neuroblastoma
17
Multiple Myeloma
17
Endometrial Neoplasms
17
Interventions
valrubicin
1
Oncolytic Virotherapy
1
Mitomycin
1
Interferons
1
Gemcitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Adenoviridae Infections
×
Genitourinary
×
Clear all
NCT01438112
2021-04-14
BOND
CG Oncology, Inc.
Phase 2/3
Terminated
22 enrolled